Bolt Biotherapeutics, Inc. filed a Form 8-K on October 23, 2026, disclosing its acquisition of Prana Therapies, Inc. through a two-step merger completed on that same date.

Key Highlights

  • Merger completed: Bolt acquired Prana Therapies, Inc. on October 23, 2026, via an Agreement and Plan of Merger dated the same day.
  • Consideration issued: Bolt issued 430,746 shares of Common Stock and 16,360.929 shares of Series D Non-Voting Convertible Preferred Stock to Prana stockholders at closing.
  • Preferred conversion ratio: Each share of Series D Preferred Stock is convertible into 1,000 shares of Common Stock, subject to certain conditions.
  • Post-merger ownership (pre-Financing): Pre-transaction Bolt equityholders hold approximately 11.8% and former Prana equityholders hold approximately 88.2% of Common Stock on a fully diluted basis, assuming conversion of Series D Preferred Stock.
  • Post-Financing ownership: Following the contemplated financing, pre-transaction Bolt equityholders are expected to hold approximately 6.9%, former Prana equityholders approximately 51.7%, and new investors approximately 41.4%, on a fully diluted basis.
  • No stockholder vote required at closing: The Board unanimously approved the Merger Agreement and the consummation of the merger did not require approval of Bolt stockholders.
  • Reverse stock split proposed: A stockholder meeting is planned to consider, among other matters, a reverse stock split at a ratio of 1:2 to 1:12 for Nasdaq compliance purposes.

Bolt Biotherapeutics Completes Two-Step Merger with Prana Therapies

According to the filing, Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) completed its acquisition of Prana Therapies, Inc. on October 23, 2026, under an Agreement and Plan of Merger executed that same day. The transaction was structured as a two-step merger: First Merger Sub, Inc. merged with and into Prana, with Prana surviving as a wholly owned subsidiary; immediately thereafter, Prana merged with and into Second Merger Sub, LLC, with Second Merger Sub as the surviving entity. The filing states the merger "is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes."

As merger consideration, the company disclosed that it issued to Prana stockholders 430,746 shares of Common Stock (par value $0.00001 per share) and 16,360.929 shares of Series D Non-Voting Convertible Preferred Stock (par value $0.00001 per share), each share of which is convertible into 1,000 shares of Common Stock subject to certain conditions. The filing notes that existing Bolt shares outstanding immediately before the merger remain outstanding and unaffected. All outstanding Prana stock options were assumed by Bolt and converted into options to purchase Bolt Common Stock.

The company reported that it plans to hold one or more stockholder meetings to address several matters, including Nasdaq approval of the Series D Preferred Stock conversion, a potential charter amendment to increase authorized shares, a possible reverse stock split at a ratio of 1:2 to 1:12 for Nasdaq listing compliance, and the adoption of new equity incentive and employee stock purchase plans. The filing also states that the company has agreed to file a Registration Statement on Form S-3 within 75 days of the closing date to register resale of shares issued in connection with the merger.

What Was Disclosed

Bolt Biotherapeutics disclosed the completion of its acquisition of Prana Therapies via a two-step merger on October 23, 2026, including the share consideration issued, resulting ownership percentages, and planned follow-on stockholder actions and filings.